Possible Impact of Merck Acqusition of Cubist on the Trius CVRMonday, December 8, 2014 · 5:19 pm |
|
Trius Therapeutics to be Acquired by Cubist (TSRX: $13.66)Wednesday, July 31, 2013 · 1:48 pm |
|
Trius: Topline Data of Second Phase III Trial of Tedizolid is Eminent (TSRX, $6.76)Monday, March 18, 2013 · 8:52 am |
|
Trius: Why Last Friday’s Equity Offering is good for the Stock (TSRX, $4.90)Monday, January 21, 2013 · 12:03 pm |
|
Trius Therapeutics: In an About Face, Congress is Helping Biotech Companies That Are Developing Antibiotics (TSRX, $5.54)Monday, January 14, 2013 · 8:30 am |
|
Settlement Between Pfizer and Teva on Generic Zyvox is a Significant Positive for Trius TherapeuticsMonday, October 29, 2012 · 10:43 am |
|
An Update on Trius Therapeutics’ Tedizolid; a Potential Blockbuster for Treating MRSA Infections (TSRX, $5.41)Wednesday, August 22, 2012 · 11:35 am |
|
Trius Therapeutics' Tedizolid has Blockbuster Potential for MRSA Infections (TSRX, $5.05)Wednesday, May 30, 2012 · 1:45 pm |
|
|
There are 8 reports on file. |
